Company intelligence / Profile preview
Atalanta Therapeutics
Boston, Massachusetts, United Statesatalantatx.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
01
Overview
Atalanta Therapeutics has developed a proprietary di-siRNA platform that enables potent, durable gene silencing throughout the brain and spinal cord. The company has demonstrated preclinical proof-of-concept for its lead programs, including sustained silencing of the huntingtin gene in animal models. IND submissions are planned for their first two programs—targeting Huntington's disease and KCNT1-related epilepsy—in late 2025. No human clinical results have been reported yet as of May 2025.[6][7]
- Therapeutic areas
- Neurology
- Modalities
- RNA interference (RNAi)Divalent small interfering RNA (di-siRNA)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Genentech/Roche – strategic collaboration on undisclosed CNS targets using di-siRNA technology[5][8].Biogen – previous partnership on Huntington's program; now unwinding with full rights reverting to Atalanta[8].
Beyond the preview
Go deeper on Atalanta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atalanta Therapeutics.